Twist Bioscience Corporation $TWST Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its stake in shares of Twist Bioscience Corporation (NASDAQ:TWST) by 67.2% in the 1st quarter, Holdings Channel reports. The institutional investor owned 25,070 shares of the company’s stock after selling 51,414 shares during the quarter. SG Americas Securities LLC’s holdings in Twist Bioscience were worth $1,191,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. EdgePoint Investment Group Inc. lifted its holdings in shares of Twist Bioscience by 71.1% in the 3rd quarter. EdgePoint Investment Group Inc. now owns 4,082,319 shares of the company’s stock valued at $114,876,000 after purchasing an additional 1,696,377 shares during the last quarter. First Light Asset Management LLC boosted its position in shares of Twist Bioscience by 26.4% in the 3rd quarter. First Light Asset Management LLC now owns 1,194,883 shares of the company’s stock valued at $33,624,000 after purchasing an additional 249,850 shares during the period. UBS Group AG grew its stake in Twist Bioscience by 28.6% during the 4th quarter. UBS Group AG now owns 662,317 shares of the company’s stock worth $21,009,000 after buying an additional 147,389 shares during the last quarter. Pictet Asset Management Holding SA grew its stake in Twist Bioscience by 108.5% during the 4th quarter. Pictet Asset Management Holding SA now owns 222,647 shares of the company’s stock worth $7,302,000 after buying an additional 115,880 shares during the last quarter. Finally, Prosight Management LP acquired a new position in Twist Bioscience during the third quarter worth approximately $2,110,000.

Insider Activity

In other Twist Bioscience news, insider Dennis Cho sold 14,205 shares of the business’s stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $89.75, for a total value of $1,274,898.75. Following the transaction, the insider directly owned 105,141 shares of the company’s stock, valued at approximately $9,436,404.75. The trade was a 11.90% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Melissa A. Starovasnik sold 500 shares of the business’s stock in a transaction on Monday, April 27th. The shares were sold at an average price of $61.83, for a total transaction of $30,915.00. Following the completion of the transaction, the director directly owned 25,222 shares in the company, valued at $1,559,476.26. This represents a 1.94% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 67,580 shares of company stock valued at $5,169,482. 3.08% of the stock is currently owned by company insiders.

Twist Bioscience Price Performance

TWST opened at $99.24 on Friday. The business has a 50 day moving average price of $70.97 and a two-hundred day moving average price of $53.83. The company has a quick ratio of 2.42, a current ratio of 2.70 and a debt-to-equity ratio of 0.03. The company has a market cap of $6.18 billion, a PE ratio of -74.62 and a beta of 2.11. Twist Bioscience Corporation has a 52 week low of $23.30 and a 52 week high of $105.47.

Twist Bioscience (NASDAQ:TWST) last announced its earnings results on Monday, May 4th. The company reported ($0.71) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.22). Twist Bioscience had a negative net margin of 19.85% and a negative return on equity of 26.73%. The company had revenue of $110.72 million during the quarter, compared to analysts’ expectations of $107.64 million. During the same quarter last year, the business posted ($0.66) earnings per share. The company’s revenue for the quarter was up 19.3% compared to the same quarter last year. As a group, research analysts anticipate that Twist Bioscience Corporation will post -2.02 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have weighed in on TWST. Canaccord Genuity Group assumed coverage on Twist Bioscience in a research note on Monday, June 15th. They issued a “buy” rating and a $90.00 price objective for the company. Barclays raised their target price on shares of Twist Bioscience from $65.00 to $95.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 24th. TD Cowen lifted their target price on shares of Twist Bioscience from $68.00 to $89.00 and gave the company a “buy” rating in a report on Monday, June 15th. Piper Sandler assumed coverage on shares of Twist Bioscience in a research report on Thursday, June 11th. They issued an “overweight” rating and a $85.00 price target for the company. Finally, Leerink Partners set a $80.00 price target on shares of Twist Bioscience in a research note on Friday, May 22nd. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $79.30.

Twist Bioscience Profile

Twist Bioscience Corporation is a synthetic biology company specializing in the development and commercialization of DNA-based products and solutions. Founded in 2013 and headquartered in South San Francisco, California, the company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides. Twist leverages semiconductor manufacturing techniques to enable precise, scalable synthesis of DNA at speeds and volumes unattainable with traditional methods.

At the core of Twist’s offering is its proprietary platform that automates the synthesis of custom DNA fragments, gene libraries, and long oligonucleotides.